Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Scibrunch Therapeutics Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and a distinct art unit. This level of concentration suggests that the company is currently focused on a specific therapeutic innovation within the biotechnology sector.
D MARGARET M SEAMAN is the busiest examiner for the company, managing the 1 pending office action. This assignment means that the primary point of contact for the company's current prosecution is the identified examiner. For the company, the outcome of the pending office action is entirely dependent on the review of the identified examiner. This requires a highly tailored prosecution strategy that addresses the specific technical and legal objections raised by this examiner, as the company's current patenting success in this area rests on this matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SEAMAN, D MARGARET M | 1 | 76.6% | +8.1% |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18862180 | FLUOROQUINOXALINONE DERIVATIVE FOR SELECTIVELY INHIBITING PARP1 | SEAMAN, D MARGARET M | 1625 | §102 | Non-Final OA | — | Pending | Nov 01, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialScibrunch Therapeutics Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
D Margaret M Seaman has the most, with 1 of Scibrunch Therapeutics Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
